

# Bajaj Auto (BAJA.BO)

## Downgrade to Neutral: Brake for a Breather After the Sprint

- Company Update
- Rating Change
- Target Price Change
- Estimate Change

- **Downgrade** — We downgrade Bajaj Auto to Neutral following the stock's sharp run-up (~33%) since July. The stock currently trades at ~16x FY14E consensus EPS. We think it will continue to trade in its current band of ~15-17x given a lack of meaningful fundamental catalysts over the next 12 months. Our revised target price of Rs2,189 (previously Rs1,835) is based on 16x Mar14E P/E. We hike our multiple from 14x to 16x (c10% premium to the average of the past 2 years) to reflect the better outlook for 3-wheelers and a sedate recovery in exports, both of which should support margins.
- **EPS revised up 4.4%/9.4% over FY14/FY15** — To reflect better pricing/realizations on account of a depreciating currency (locked in at ~Rs54/\$ on the downside in FY14). We cut export volumes (both 2&3w) sharply – around 8-15%, to reflect a lower than expected FY13 and also a more muted growth outlook (10-12%) than previously envisaged (15-20%). Domestic 3w volumes have been revised up sharply (+10%/5% in FY14/15 respectively); 2w volumes are broadly unchanged.
- **Stable market share forecast across segments** — We expect a slight (~100bps) compression in market share in the executive segment as we expect the space to become more competitive with Honda's new launches (anticipate 2 bikes). Bajaj's strategy of segmenting the market and launching new variants will have limited appeal in the short run (given significant cannibalization with other models), though it could improve over the longer term. Within the premium/economy segments we expect Bajaj to be able to retain its current market share.
- **Bajaj better positioned than peers in the sector** — We are now neutral on the sector, with a slight negative bias, given share price performance in the past few months. Volumes must keep pace with share price performance or else the sector will see a fairly sharp sell-off. Tata Motors is now our preferred pick. We also prefer Bajaj to Maruti / Mahindra & Mahindra given its relatively low volatility of earnings, dividend yield of ~3% and very strong free cash flow generation.

<b>Neutral</b>	<b>2</b>
<i>from Buy</i>	
Price (01 Feb 13)	Rs2,053.45
Target price	Rs2,189.00
<i>from Rs1,835.00</i>	
Expected share price return	6.6%
Expected dividend yield	3.2%
<b>Expected total return</b>	<b>9.8%</b>
Market Cap	Rs594,201M
	US\$11,153M

### Price Performance (RIC: BAJA.BO, BB: BJAUT IN)



### Statistical Abstract

Year to	Net Profit	Diluted EPS	EPS growth	P/E	P/B	ROE	Yield
31 Mar	(RsM)	(Rs)	(%)	(x)	(x)	(%)	(%)
2011A	27,835	96.19	53.2	21.3	12.1	71.0	1.9
2012A	31,040	107.27	11.5	19.1	9.8	56.7	2.2
2013E	31,544	109.01	1.6	18.8	7.4	44.8	2.4
2014E	39,597	136.84	25.5	15.0	6.0	44.3	3.2
2015E	45,716	157.99	15.5	13.0	5.0	42.1	3.7

Source: Powered by dataCentral

### Jamshed Dadabhoy

+65-6657-1146  
jamshed.dadabhoy@citi.com

### Arvind Sharma

+91-22-6631-9852  
arvind1.sharma@citi.com

### See Appendix A-1 for Analyst Certification, Important Disclosures and non-US research analyst disclosures.

Citi Research is a division of Citigroup Global Markets Inc. (the "Firm"), which does and seeks to do business with companies covered in its research reports. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision.

BAJA.BO: Fiscal year end 31-Mar						Price: Rs2,053.45; TP: Rs2,189.00; Market Cap: Rs594,201m; Recomm: Neutral					
Profit & Loss (Rsm)						Valuation ratios					
	2011	2012	2013E	2014E	2015E		2011	2012	2013E	2014E	2015E
Sales revenue	165,768	196,077	203,474	235,245	271,349	PE (x)	21.3	19.1	18.8	15.0	13.0
Cost of sales	-119,217	-142,605	-146,312	-164,295	-189,812	PB (x)	12.1	9.8	7.4	6.0	5.0
Gross profit	46,551	53,473	57,162	70,951	81,537	EV/EBITDA (x)	17.1	14.5	13.4	10.2	8.6
Gross Margin (%)	28.1	27.3	28.1	30.2	30.0	FCF yield (%)	6.0	6.0	5.3	7.4	8.2
<b>EBITDA (Adj)</b>	<b>33,528</b>	<b>37,988</b>	<b>40,161</b>	<b>50,987</b>	<b>58,407</b>	Dividend yield (%)	1.9	2.2	2.4	3.2	3.7
EBITDA Margin (Adj) (%)	20.2	19.4	19.7	21.7	21.5	Payout ratio (%)	42	42	46	48	47
Depreciation	-1,228	-1,456	-1,605	-1,794	-2,079	ROE (%)	85.2	54.9	44.8	44.3	42.1
Amortisation	0	0	0	0	0	<b>Cashflow (Rsm)</b>	<b>2011</b>	<b>2012</b>	<b>2013E</b>	<b>2014E</b>	<b>2015E</b>
<b>EBIT (Adj)</b>	<b>32,299</b>	<b>36,531</b>	<b>38,556</b>	<b>49,193</b>	<b>56,328</b>	EBITDA	33,528	37,988	40,161	50,987	58,407
EBIT Margin (Adj) (%)	19.5	18.6	18.9	20.9	20.8	Working capital	2,638	5,463	1,771	5,005	3,856
Net interest	-17	-222	-150	-150	-150	Other	1,098	-6,491	-7,013	-9,596	-10,612
Associates	0	0	0	0	0	<b>Operating cashflow</b>	<b>37,263</b>	<b>36,959</b>	<b>34,920</b>	<b>46,397</b>	<b>51,651</b>
Non-op/Except	3,980	5,293	6,336	7,525	9,131	Capex	-1,500	-1,207	-3,520	-2,520	-3,030
<b>Pre-tax profit</b>	<b>36,262</b>	<b>41,602</b>	<b>44,743</b>	<b>56,568</b>	<b>65,309</b>	Net acq/disposals	-7,737	-876	-17,721	-18,988	-16,692
Tax	-10,110	-10,221	-13,199	-16,970	-19,593	Other	0	0	0	0	0
Extraord./Min.Int./Pref.div.	7,246	-1,340	0	0	0	<b>Investing cashflow</b>	<b>-9,237</b>	<b>-2,083</b>	<b>-21,241</b>	<b>-21,508</b>	<b>-19,722</b>
<b>Reported net profit</b>	<b>33,397</b>	<b>30,041</b>	<b>31,544</b>	<b>39,597</b>	<b>45,716</b>	Dividends paid	-13,452	-15,134	-16,816	-21,860	-25,223
Net Margin (%)	20.1	15.3	15.5	16.8	16.8	<b>Financing cashflow</b>	<b>-22,140</b>	<b>-17,411</b>	<b>-16,790</b>	<b>-21,660</b>	<b>-24,923</b>
Core NPAT	27,835	31,040	31,544	39,597	45,716	<b>Net change in cash</b>	<b>5,886</b>	<b>17,466</b>	<b>-3,111</b>	<b>3,229</b>	<b>7,006</b>
<b>Per share data</b>	<b>2011</b>	<b>2012</b>	<b>2013E</b>	<b>2014E</b>	<b>2015E</b>	<b>Free cashflow to s/holders</b>	<b>35,763</b>	<b>35,752</b>	<b>31,400</b>	<b>43,877</b>	<b>48,621</b>
Reported EPS (Rs)	115.41	103.81	109.01	136.84	157.99						
Core EPS (Rs)	96.19	107.27	109.01	136.84	157.99						
DPS (Rs)	40.00	45.00	50.00	65.00	75.00						
CFPS (Rs)	128.77	127.72	120.68	160.34	178.49						
FCFPS (Rs)	123.59	123.55	108.51	151.63	168.02						
BVPS (Rs)	169.69	208.77	278.29	339.59	410.41						
Wtd avg ord shares (m)	289	289	289	289	289						
Wtd avg diluted shares (m)	289	289	289	289	289						
<b>Growth rates</b>	<b>2011</b>	<b>2012</b>	<b>2013E</b>	<b>2014E</b>	<b>2015E</b>						
Sales revenue (%)	39.3	18.3	3.8	15.6	15.3						
EBIT (Adj) (%)	32.8	13.1	5.5	27.6	14.5						
Core NPAT (%)	53.2	11.5	1.6	25.5	15.5						
Core EPS (%)	53.2	11.5	1.6	25.5	15.5						
<b>Balance Sheet (Rsm)</b>	<b>2011</b>	<b>2012</b>	<b>2013E</b>	<b>2014E</b>	<b>2015E</b>						
Cash & cash equiv.	5,565	16,538	16,737	18,366	23,972						
Accounts receivables	3,628	4,228	4,589	5,453	6,287						
Inventory	5,473	6,785	7,410	8,640	10,136						
Net fixed & other tangibles	15,483	15,234	17,149	17,875	18,826						
Goodwill & intangibles	43	14	20	20	20						
Financial & other assets	62,013	68,011	89,549	112,537	133,229						
<b>Total assets</b>	<b>92,204</b>	<b>110,811</b>	<b>135,453</b>	<b>162,891</b>	<b>192,470</b>						
Accounts payable	21,578	22,071	24,609	27,765	32,087						
Short-term debt	0	0	0	0	0						
Long-term debt	3,252	975	1,000	1,200	1,500						
Provisions & other liab	18,272	27,354	29,316	35,660	40,123						
<b>Total liabilities</b>	<b>43,101</b>	<b>50,400</b>	<b>54,924</b>	<b>64,625</b>	<b>73,711</b>						
Shareholders' equity	49,102	60,411	80,529	98,266	118,759						
Minority interests	0	0	0	0	0						
<b>Total equity</b>	<b>49,102</b>	<b>60,411</b>	<b>80,529</b>	<b>98,266</b>	<b>118,759</b>						
<b>Net debt</b>	<b>-2,313</b>	<b>-15,564</b>	<b>-15,737</b>	<b>-17,166</b>	<b>-22,472</b>						
Net debt to equity (%)	-4.7	-25.8	-19.5	-17.5	-18.9						

For further data queries on Citi's full coverage universe please contact Citi Research Data Services at CitiRsch.DataServices.Global@citi.com  
For definitions of the items in this table, please click [here](#).

# Valuation Speed Breaker: Time for a Breather


We continue to wield the axe on our auto sector recommendations. Following our downgrade on Maruti Suzuki ([Maruti Suzuki India \(MRTI.BO\) - The Macro Micro Disconnect – Downgrade to Neutral](#)) we now downgrade Bajaj Auto to Neutral with a target price of Rs2,189 at 16x FY14E P/E. Bajaj Auto's stock price has risen almost 33% since July, and while we remain fairly constructive on the business outlook over the next 12-24 months, we do think the valuation hurdle is a bit steep at this juncture. Given both stocks have rallied sharply in the past 6 months (Bajaj/Maruti up 27%/43% respectively), we think a pullback in both stocks is possible. Logically though, it should be a bit less in Bajaj (vs. MSIL), as Bajaj's cash flow stream is far more defensive, and conversion of PAT into free cash is very high (>90%).

Our 16x multiple is slightly on the higher side, and it is at a 10% premium to the average of the past two years. We think that it should be well supported by earnings growth of around 20% CAGR over FY13-FY15E. We expect the re-rating should sustain, provided Bajaj a) doesn't cede too much market share in the domestic market to Hero, b) maintains its margins at around 18-20%, c) continues to grow market share in the export markets and thrust into new markets (Indonesia for 2 wheelers with Kawasaki and then Brazil – with KTM and Kawasaki). At our target price, the stock would trade at a multiple of around 6.5x, which is fairly substantial but supported by the 44-45% RoE that we forecast going forward.

Our downgrade is predicated on the following aspects:


**1 – Valuations** – we think Bajaj's valuations at current levels reflect its strong franchise in 3-wheelers, exports and the premium 2-wheeler space. As the charts below depict, absolute P/E at nearly 17x is almost at an all-time high. Valuations are also above 1SD. We think there should be a slight upward bias given the relatively short trading history – Bajaj restructured in 2007 and re-listed in 2008 – around the time of the financial crisis. However, even vis-à-vis an average P/E of say 12-13x, the stock is overvalued at this juncture.

**Figure 1. Bajaj Auto: PE relative to Hero MotoCorp**




Source: Company, dataCentral, Citi Research

**Figure 2. Bajaj Auto: P/EPS (x) band chart**



Source: Company, dataCentral, Citi Research


**Figure 3. Bajaj Auto: 1 yr fwd P/E trends**



Source: Company, dataCentral, Citi Research


**2 – The ‘blind spot’ vis-à-vis Honda** – In our conversations with investors, most investors reckon that while Hero will be meaningfully impacted by Honda, Bajaj will be relatively unscathed. This view is a volte-face on the view held last year, that Honda’s urban centric model would impact Bajaj and Hero would be better positioned given its rural thrust and scale and distribution network. We think this is incorrect too. As the data below indicates, Bajaj Auto has lost market share over FY13 in the economy and premium segments – though it has gained slightly in the premium segment. As Honda becomes more aggressive, we would expect the company to maintain share – rather than recoup market share.

**Figure 4. Bajaj’s Mkt Sh (%), Domestic Economy**




Source: CRISIL, SIAM, Citi Research

**Figure 5. Bajaj’s Mkt Sh (%), Domestic Executive**




Source: CRISIL, SIAM, Citi Research

**Figure 6. Bajaj’s Mkt Sh (%), Domestic Premium**



Source: CRISIL, SIAM, Citi Research


**Figure 7. EBITDA Mix FY13 (%)**



Source: Citi Research

**3 – Domestic business is irrelevant – the way ahead is exports. We disagree with this thought process.** Per our estimates, the domestic 2w business in FY13E accounts for around 35% of EBITDA. And while one could argue that its proportion will only decline going forward over the next 5 years, we think this will be relevant maybe 4-5 years down the line, once exports to Indonesia and Brazil are meaningfully in the base. From a nearer 12-24 month perspective, the domestic business will remain very important.

**Figure 8. Bajaj’s Export Markets (FY12)**



Source: Company

**4 – Rupee provides a significant cushion in FY14 – it does – and we reflect this benefit in our revised earnings** – we forecast Rs136.84/share EPS in FY14 – and this meaningful uptick (vis-à-vis our previous Rs107 estimate in FY13) is driven to a great extent by better export realizations. There are however 2 risks, that we also think are worth articulating. A) In the event of a continued slowdown in both domestic/export markets, Bajaj might cut prices and pass on the currency benefit to drive volumes – this is pragmatic, but could result in an EPS miss (not reflected in expectations, which range from Rs130-Rs140 / share). B) The government further cuts the duty drawback/focus market scheme benefits – over 2 years, the government has reduced this benefit from ~10% to ~4%. The impact has not been reflected substantially due to the sharp depreciation of the Rupee from 45-55/US\$. But if the government reckons that a) exporters are making sufficiently high margins and b) it needs to shore up its own finances, and cuts this benefit, then there would be an overall impact of ~150-200 bps on margins, which is not factored into these earnings/valuations.

### Earnings Revision – Profits go up, volumes go down

We have pared volumes across 2w and 3w – the only exception being domestic 3w where we have increased volumes given the strong volume growth YTD and expectations of further permits being issued. The outlook on exports is in line with management's views – most key end markets continue to struggle slightly, given the macro environment.


Profits go up – driven by higher financial income, also boosted by better realizations in exports (INR depreciation).

Figure 9. Bajaj Auto: Earnings Revision

	Old			New			Change		
	FY13	FY14	FY15	FY13	FY14	FY15	FY13	FY14	FY15
Domestic Motorcycles	2,589,049	2,797,776	3,115,281	2,563,126	2,790,727	3,133,287	-1.0%	-0.3%	0.6%
% Chg YoY	0.9%	8.1%	11.3%	-0.1%	8.9%	12.3%			
Export Motorcycles	1,394,413	1,603,575	1,924,290	1,309,694	1,466,857	1,713,543	-6.1%	-8.5%	-11.0%
% Chg YoY	10.0%	15.0%	20.0%	3.3%	12.0%	16.8%			
<b>Total Motorcycles</b>	<b>3,983,462</b>	<b>4,401,350</b>	<b>5,039,571</b>	<b>3,872,820</b>	<b>4,257,584</b>	<b>4,846,830</b>	<b>-2.8%</b>	<b>-3.3%</b>	<b>-3.8%</b>
% Chg YoY	3.9%	10.5%	14.5%	1.0%	9.9%	13.8%			
Domestic 3Ws	207,039	217,391	228,260	223,277	238,906	238,906	7.8%	9.9%	4.7%
% Chg YoY	2.0%	5.0%	5.0%	10.0%	7.0%	0.0%			
Export 3Ws	280,958	337,150	387,723	265,350	291,885	326,911	-5.6%	-13.4%	-15.7%
% Chg YoY	-10.0%	20.0%	15.0%	-15.0%	10.0%	12.0%			
<b>Total 3Ws</b>	<b>487,997</b>	<b>554,541</b>	<b>615,983</b>	<b>488,627</b>	<b>530,791</b>	<b>565,817</b>	<b>0.1%</b>	<b>-4.3%</b>	<b>-8.1%</b>
% Chg YoY	-5.3%	13.6%	11.1%	-5.1%	8.6%	6.6%			
Total Domestic Volumes	2,796,088	3,015,166	3,343,541	2,786,403	3,029,633	3,372,193	-0.3%	0.5%	0.9%
% Chg YoY	1.0%	7.8%	10.9%	0.6%	8.7%	11.3%			
Total Export Volumes	1,675,371	1,940,725	2,312,012	1,575,044	1,758,742	2,040,454	-6.0%	-9.4%	-11.7%
% Chg YoY	6.0%	15.8%	19.1%	-0.3%	11.7%	16.0%			
<b>Overall Volumes</b>	<b>4,471,459</b>	<b>4,955,891</b>	<b>5,655,554</b>	<b>4,361,447</b>	<b>4,788,375</b>	<b>5,412,647</b>	<b>-2.5%</b>	<b>-3.4%</b>	<b>-4.3%</b>
% Chg YoY	2.8%	10.8%	14.1%	0.3%	9.8%	13.0%			
<b>Total Income</b>	<b>205,997</b>	<b>236,750</b>	<b>270,129</b>	<b>203,474</b>	<b>235,245</b>	<b>271,349</b>	<b>-1.2%</b>	<b>-0.6%</b>	<b>0.5%</b>
<b>EBITDA</b>	<b>40,706</b>	<b>51,041</b>	<b>55,693</b>	<b>40,161</b>	<b>50,987</b>	<b>58,407</b>	<b>-1.3%</b>	<b>-0.1%</b>	<b>4.9%</b>
EBITDA Margin	19.8%	21.6%	20.6%	19.7%	21.7%	21.5%			
<b>PAT</b>	<b>31,037</b>	<b>37,926</b>	<b>41,780</b>	<b>31,544</b>	<b>39,597</b>	<b>45,716</b>	<b>1.6%</b>	<b>4.4%</b>	<b>9.4%</b>
<b>EPS</b>	<b>107.26</b>	<b>131.06</b>	<b>144.38</b>	<b>109.01</b>	<b>136.84</b>	<b>157.99</b>	<b>1.6%</b>	<b>4.4%</b>	<b>9.4%</b>


Source: Citi Research Estimates

Figure 10. Bajaj: Overall 3W Volume Trends




Source: Company, Citi Research

Figure 11. Bajaj: Domestic 3W Volume Trends



Source: Company, Citi Research

Figure 12. Bajaj: Export 3W Volume Trends




Source: Company, Citi Research

Within domestic 3w, the 10% growth estimate in FY13 reflects the 9MYTD run rate, and an expectation that domestic volumes will grow ~55,000-60,000 units in the last Q (current run rate). The FY14 estimate of around 239,000 units is based on mgmt's view that the current run rate of ~19,000 units / month is sustainable through next year. To this, we have added around 10,000 units on expectations of new permits being granted (mgmt noted there should be around 20,000 new permits in Hyderabad – we assume Bajaj will get 50% of these). In FY15, our volume estimates reflect flat growth. Typically after 2 strong years, the domestic 3w market flat lines for 1-2 years. Moreover with general elections in late FY14/early FY15, we expect all state/municipal departments will be in 'election mode' and would not be very positive on new permits being issued in that fiscal.


For export 3w, the FY13 estimate reflects the 9MYTD numbers and an expectation that the run rate of the last Q (around 75,000 units) will be maintained even going into 4Q. On this base, for FY14 we forecast growth of around 10% - which translates into monthly sales of around 24,000 units/ month – in the middle of mgmt's estimate of 22,000-25,000 units/ month. For FY15, we then forecast a slight acceleration in growth rates to around 12% as we expect key markets like Sri Lanka, Egypt to rebound after a slightly challenging FY13/FY14.

Figure 13. Bajaj: Overall 2W Volume Trends




Source: Company, Citi Research

Figure 14. Bajaj: Domestic Motorcycles Volume Trends



Source: Company, Citi Research

Figure 15. Bajaj: Export Motorcycles Volume Trends




Source: CRISIL Citi Research

For export 2ws, we expect volumes to grow 3.3% in FY13, which is essentially a run rate of 320k bikes in 4Q added to the 9mYTD estimate. The 12% growth factored in FY14 is at the higher end of the 10-12% range that we think is possible given conditions in end markets like Sri Lanka. Finally, in FY15 our growth rate of 17% reflects a 12% organic growth rate and around 100k units from new markets entered


– principally Indonesia (with Kawasaki) and maybe a few months of Brazil. There is upside risk to the FY15 estimates, but it depends on management’s ability to execute over the next 12-18 months.

**Figure 16. Bajaj: Domestic Econ Segment Bike Growth (%)**




Source: CRISIL, SIAM, Citi Research

**Figure 17. Bajaj: Domestic Exec Segment Bike Growth (%)**



Source: CRISIL, SIAM, Citi Research

**Figure 18. Bajaj: Domestic Premium Segment Bike Growth (%)**



Source: CRISIL, SIAM, Citi Research

Our estimates for domestic 2 wheelers flow through a top-down industry model, wherein we assess the relative growth of the segments and assess the market share of Bajaj Auto within each segment.

Referring to Figs.16-18, we expect Bajaj to cede market share very slightly in the executive segment – around 100bps, based on our expectation that Honda will launch at least 2 bikes in this segment. This, despite the launch of the Discover 100T – Bajaj’s ‘varianting’ strategy is impressive and could benefit volumes in an industry upturn; in a modest recovery phase we expect the model to cannibalize its peers to the extent of 60-70% - net growth is thus more modest.

### 2W Industry Outlook – Chugging Along


Our volume outlook for FY14/FY15 reflects fairly average growth – of around 12% Y/Y for both FY14/FY15. Reality will probably be different (it always is). While we forecast 12%, we think that around 10-15% is reasonable, given the following:

- 1) Base effect of FY13 is somewhat subdued (following a 14% volume growth in FY12),
- 2) Real wage growth in rural India should begin to decelerate – but the base of the past 2 years will make its effects felt.
- 3) Any rural linked programs in the backdrop of a 2014 election should also be beneficial for rural consumer sentiment – which should reflect in volumes.
- 4) Based on our assumptions for both terminal life / scrappage rates, by FY15 2W penetration should be around 108/1000 – our terminal life assumption is 15 years and our parc size in FY15 (all 2w) should be around 136m units. This equates to a 10% penetration rate. In the past, 10% was considered high as the ‘addressable population’ was considered to be only males in the age group of 16-55/60. But we think this is slowly changing driven by 3 factors: A) product availability – the scooter has made a resurgence and is probably going to become more mainstream as OEMs

increase distribution / after-sales support and increase dealer networks in smaller towns. B) More women / young girls / older men are driving scooters – demand is thus broad basing away from only bikes to scooters too, C) Scooter sales are also increasing as the quality of tarred roads improves in India’s smaller towns / villages. If one travels through smaller towns / villages in states where road quality has improved meaningfully (we cite Gujarat as one example where we saw this) then the scooter will continue to gradually increase as % of sales. The traditional bike with its sturdy shock absorbers will gradually become a product that is less about utility and merely transport to a product that is also associated with leisure applications. This is – we think – a secular trend and will continue to play out over the years, supporting a higher penetration level.


If one sees the figure below, in markets like Indonesia / Vietnam, Thailand – the penetration rates are much higher, but again, we think this is on account of higher proportion of a) mopeds / scooters in the mix, rather than just bikes, and b) a more broad-based consumer segment.

Figure 19. 2 Wheeler Industry Volume Outlook



Source: CRISIL, SIAM, Citi Research

Figure 20. Motorcycle Penetration Rate vs Per Capita GDP




Source: Yamaha

Our assumptions above lead us to think that scooters should continue to gradually increase as % of 2w volumes – after the sharp rise from ~17.6%-21% over FY11-FY13 (driven mostly by capacity expansion by Honda/Hero), we expect it to somewhat stabilize at around 21-22% of the overall volumes, though the upward bias will probably continue over time, supported by demographics (more women riders, older men, dual rider products), OEMs themselves (products, distribution) and finally supporting infrastructure (better road quality, especially in smaller towns).




Figure 21. 2 Wheeler Industry Mix Outlook



Source: CRISIL, SIAM, Citi Research


Figure 22. Domestic Motorcycles: Volume Outlook



Source: CRISIL, SIAM, Citi Research


Within overall 2 wheelers, motorcycles should remain fairly steady at around 73%, as Honda looks to grow its market share in bikes, rather than scooters. This along with regular product introductions by Honda, Hero and Bajaj should ensure that the segment remains at around 73-74% of volumes, though longer term it should continue to decline as it cedes share to motorcycles. After FY13's weak base, we expect the segment to grow ~12% CAGR over the next 2 years.

Figure 23. Domestic Motorcycles: Segmental Volume Growth



Source: Citi Research

Figure 24. Domestic Motorcycles: Segmental Split



Source: CRISIL, SIAM, Citi Research

The general bias for the next 2 years is a slight upgradation trend – reversing the trends seen over FY12-FY13. We expect growth to be a tad more urban, rather than rural, and also expect players (notably Bajaj and Honda) to position new products in the premium 100cc segment (around Rs45,000-Rs50,000 segment) and the 125cc / 150cc segments, which should also stimulate growth and encourage a slight upward shift.

## Financial Statements

Figure 25. Bajaj Auto: Profit and Loss Statement (Rs mn except volumes (units))

	FY2010	FY2011	FY2012	FY2013E	FY2014E	FY2015E
<b>Volumes</b>	<b>2,852,536</b>	<b>3,823,954</b>	<b>4,349,560</b>	<b>4,361,447</b>	<b>4,788,375</b>	<b>5,412,647</b>
% Change YoY	30.0%	34.1%	13.7%	0.3%	9.8%	13.0%
<b>Gross Sales</b>	<b>121,180.8</b>	<b>169,315</b>	<b>198,270</b>	<b>209,366</b>	<b>242,747</b>	<b>279,858</b>
Excise	6,096	9,334	9,468	11,554	12,910	14,829
<b>Net Sales</b>	<b>115,085</b>	<b>159,981</b>	<b>188,803</b>	<b>197,812</b>	<b>229,837</b>	<b>265,029</b>
Other operating Income	3,881	5,786	7,275	5,662	5,409	6,320
<b>Net Revenue</b>	<b>118,966</b>	<b>165,768</b>	<b>196,077</b>	<b>203,474</b>	<b>235,245</b>	<b>271,349</b>
Raw Material Expense	80,704.4	117,988	141,149	144,707	162,501	187,733
% of Net Revenue	67.8%	71.2%	72.0%	71.1%	69.1%	69.2%
Other variable expense	3,759,000	4,742.5	5,734	6,040	7,366	8,650
% of Net Revenue	3.2%	2.9%	2.9%	3.0%	3.1%	3.2%
Employee Expense	3,995	4,935.8	5,401	6,211	7,143	8,214
% of Net Revenue	3.4%	3.0%	2.8%	3.1%	3.0%	3.0%
Other Fixed Expense	4,983	4,740.3	6,301	6,854	7,749	8,844
% of Net Revenue	4.2%	2.9%	3.2%	3.4%	3.3%	3.3%
<b>Expenses Capitalised</b>	<b>157</b>	<b>167</b>	<b>494</b>	<b>500</b>	<b>500</b>	<b>500</b>
<b>Total Expense</b>	<b>93,284</b>	<b>132,240</b>	<b>158,090</b>	<b>163,313</b>	<b>184,258</b>	<b>212,943</b>
<b>EBITDA</b>	<b>25,681</b>	<b>33,528</b>	<b>37,988</b>	<b>40,161</b>	<b>50,987</b>	<b>58,407</b>
<b>EBITDA Margin (%)</b>	<b>21.6%</b>	<b>20.2%</b>	<b>19.4%</b>	<b>19.7%</b>	<b>21.7%</b>	<b>21.5%</b>
Other Income	1,469	3,980	5,293	6,336	7,525	9,131
Interest	60	17	222	150	150	150
EBDT	27,091	37,490	43,058	46,348	58,362	67,388
Depreciation	1,365	1,228	1,456	1,605	1,794	2,079
Exceptional	(1,650)	7,246	(1,340)	-	-	-
PBT	24,076	43,508	40,262	44,743	56,568	65,309
Tax	7,075	10,110	10,221	13,199	16,970	19,593
<b>PAT</b>	<b>17,001</b>	<b>33,397</b>	<b>30,041</b>	<b>31,544</b>	<b>39,597</b>	<b>45,716</b>
% of Net Revenue	14.3%	20.1%	15.3%	15.5%	16.8%	16.8%
<b>Pre-exceptional PAT</b>	<b>18,166</b>	<b>27,835</b>	<b>31,040</b>	<b>31,544</b>	<b>39,597</b>	<b>45,716</b>
<b>Profitability Ratios (% of Net sales)</b>						
Raw mat / sales	70.1%	73.8%	74.8%	73.2%	70.7%	70.8%
Other var exp / net sales	3.3%	3.0%	3.0%	3.1%	3.2%	3.3%
Employee cost / net sales	3.5%	3.1%	2.9%	3.1%	3.1%	3.1%
Tax / PBT	29.4%	23.2%	25.4%	29.5%	30.0%	30.0%
Excise / Gross sales	5.4%	5.9%	5.1%	6.0%	5.8%	5.8%
PAT / Net sales	15.8%	17.4%	16.4%	15.9%	17.2%	17.2%
<b>EPS</b>	<b>62.78</b>	<b>96.19</b>	<b>107.27</b>	<b>109.01</b>	<b>136.84</b>	<b>157.99</b>

Source: Company, Citi Research Estimates

Figure 26. Bajaj Auto: Balance Sheet (Rs mn)

	FY2010	FY2011	FY2012	FY2013E	FY2014E	FY2015E
<b>SOURCES OF FUNDS</b>						
Share Capital	1,447	2,894	2,894	2,894	2,894	2,894
Reserves and Surplus	27,837	46,209	57,517	77,635	95,372	115,865
<b>Net Worth</b>	<b>29,283</b>	<b>49,102</b>	<b>60,411</b>	<b>80,529</b>	<b>98,266</b>	<b>118,759</b>
Deferred tax Liability	17	297	484	500	500	500
<b>Total Debt</b>	<b>13,386</b>	<b>3,252</b>	<b>975</b>	<b>1,000</b>	<b>1,200</b>	<b>1,500</b>
Other long term liabilities			1,571	1,600	1,800	2,000
Long term provisions			1,119	1,200	1,400	1,800
<b>Total Sources of funds</b>	<b>42,686</b>	<b>52,651</b>	<b>64,559</b>	<b>84,829</b>	<b>103,166</b>	<b>124,559</b>
<b>APPLICATION OF FUNDS</b>						
Gross Block	33,793	33,909	33,939	37,439	39,939	42,939
Less: Depreciation	18,997	19,125	19,143	20,748	22,542	24,621
<b>Net Block</b>	<b>14,796</b>	<b>14,784</b>	<b>14,796</b>	<b>16,691</b>	<b>17,397</b>	<b>18,318</b>
Capital WIP	415	699	118	118	118	118
Intangible assets			21	40	40	40
Intangible assets under development			299	300	320	350
<b>Net Fixed Assets</b>	<b>15,211</b>	<b>15,483</b>	<b>15,234</b>	<b>17,149</b>	<b>17,875</b>	<b>18,826</b>
<b>Total Investments</b>	<b>40,215</b>	<b>47,952</b>	<b>48,828</b>	<b>66,549</b>	<b>85,537</b>	<b>102,229</b>
Long term loans and advance			5,799	8,000	10,000	12,000
Inventories	4,462	5,473	6,785	7,410	8,640	10,136
Sundry debtors	2,728	3,628	4,228	4,589	5,453	6,287
Cash & Bank Balances	1,014	5,565	16,538	16,737	18,366	23,972
Loans & advances	20,745	11,896	10,428	12,000	14,000	16,000
Others	1,060	2,164	2,956	3,000	3,000	3,000
<b>Total current assets</b>	<b>30,010</b>	<b>28,726</b>	<b>40,936</b>	<b>43,736</b>	<b>49,460</b>	<b>59,395</b>
Sundry Creditors	18,192	21,578	22,071	24,609	27,765	32,087
Others	2,071	2,689	3,550	3,600	4,200	4,500
Provisions :						
Taxation	14,171	30	90	100	100	100
Dividends & dividend tax	6,749	13,452	15,134	16,816	21,860	25,223
Others	1,568	1,804	5,406	5,500	5,800	6,000
<b>Total current liabilities</b>	<b>42,750</b>	<b>39,553</b>	<b>46,252</b>	<b>50,624</b>	<b>59,725</b>	<b>67,911</b>
<b>Net current assets</b>	<b>(12,740)</b>	<b>(10,827)</b>	<b>(5,316)</b>	<b>(6,889)</b>	<b>(10,265)</b>	<b>(8,516)</b>
Technical know how	-	43	-	-	-	-
Misc Exp not written off (VRS)	-	-	-	-	-	-
Other non current assets			14	20	20	20
<b>Total Application of Funds</b>	<b>42,686</b>	<b>52,651</b>	<b>64,559</b>	<b>84,829</b>	<b>103,166</b>	<b>124,559</b>

Source: Company, Citi Research Estimates

### Companies Mentioned

Honda Motor (7267.T; ¥3,515; 1); Yamaha Motor (7272.T; ¥1,132; 1); Bajaj Auto (BAJA.BO; Rs2,053.45; 1); Hero MotoCorp (HROM.BO; Rs1,813.35; 3); Mahindra & Mahindra (MAHM.BO; Rs885.95; 2); Maruti Suzuki India (MRTI.BO; Rs1,608.70; 2); Tata Motors (TAMO.BO; Rs285.00; 1)



# Quants View – Glamour

**Paul Chanin**  
+65-6432-1153  
paul.chanin@citi.com

Data as of: 25-Jan-13


Bajaj Auto lies in the Glamour quadrant of our Value-Momentum map with strong momentum but relatively weak value scores. The stock has moved from the Unattractive quadrant to the Glamour quadrant in the past three months indicating an improvement in the momentum scores although valuation still remains expensive. Compared with its peers in the Automobiles & Components sector, Bajaj Auto fares worse on the valuation metric but better on the momentum metric. On the other hand, compared with its peers in its home market of India, Bajaj Auto fares worse on the valuation metric and on the momentum metric.

From a macro perspective, Bajaj Auto has a low beta to the region, so can be expected to hold its own given a decline in the regional market. It is also likely to benefit from large-cap outperformance, widening Asian interest rates, and a weaker US dollar.

## Radar Screen Quadrant Definitions


<b>Glamour</b> Poor relative value but superior relative momentum	<b>Attractive</b> Superior relative value and superior relative momentum
<b>Unattractive</b> Poor relative value and poor relative momentum	<b>Contrarian</b> Superior relative value but poor relative momentum

Figure 27. Radar Quadrant Chart History



Source: Citi Research

Figure 28. Radar Valuation and Momentum Scores



Source: Citi Research

Figure 29. Radar Model Inputs

### IBES EPS (Actual and Estimates)

FY(-2)	55.20	Implied Trend Growth (%)	17.81
FY(-1)	90.83	Trailing PE (x)	19.77
FY0	109.82	Implied Cost of Debt (%)	9.29
FY1	109.77	Standardised MCap	0.16
FY2	134.84		

Note: Standardised MCap calculated as a Z score - (mkt cap - mean)/std dev - capped at 3

Source: Citi Research, Worldscope, I/B/E/S

Figure 30. Stock Performance Sensitivity to Key Macro Factors

Region	0.58	Commodity ex Oil	(0.07)
Widening APACxJ CDS	(0.01)	Rising Oil Prices	(0.16)
Growth	(0.58)	Rising Asian IR's	0.56
Value	(0.81)	Rising EM Yields	0.00
Small Caps Outperform Large Caps	(1.12)	Weaker US\$ (vs Asia)	2.12
Widening US Credit Spreads	0.07	Weaker ¥ (vs US\$)	0.12

Source: Citi Research

## Bajaj Auto

### Company description

Bajaj Auto (BAL) is a leading domestic auto OEM that is well positioned in the motorcycle segment as the 2nd largest player with around 25% market share, and is the largest player in the 3-wheeler industry with 55% market share.

### Investment strategy

We rate Bajaj Auto as Neutral (2). Bajaj Auto stock has gone up ~27% over the last 6 months, outperforming the broader market by ~13%. While depreciating INR should buoy export earnings and Bajaj should be able to maintain a stable market share in the domestic 2 wheeler market, we believe that the current valuations price in the positives. We also believe that Bajaj's strategy of segmenting the market and launching new variants will have limited appeal in the short run (given significant cannibalization with other models), though it could improve over the longer term. We do not expect material upsides to the stock price from current levels, given a lack of meaningful fundamental catalysts.

### Valuation

We value Bajaj Auto at Rs 2,189 based on 16x FY14E EPS. Our 16x multiple is slightly on the higher side, and it is at a 10% premium to the average of the past two years. We think that it should be well supported by earnings growth of around 20% CAGR over FY13-FY15E. We expect the re-rating should sustain, provided Bajaj a) doesn't cede too much market share in the domestic market to Hero, b) maintains its margins at around 18-20%, c) continues to grow market share in the export markets and thrust into new markets (Indonesia for 2 wheelers with Kawasaki and then Brazil – with KTM and Kawasaki). At our target price, the stock would trade at a multiple of around 6.5x, which is fairly substantial but supported by the 44-45% RoE that we forecast going forward.

### Risks

The key downside risks to our investment thesis and target price on Bajaj Auto include: 1) Lower than forecast export growth in aggregate, driven by political/economic uncertainty in key end markets like Nigeria, Sri Lanka, Iran, Colombia, Egypt, etc. 2) Erosion of Bajaj's market share in the domestic Premium segment by competition - principally players like Hero, Yamaha and Honda. Key upside risks include 1) Better than expected growth in the overall domestic 2 wheeler industry with Bajaj maintaining its market share; and 2) further depreciation in INR, resulting in better export realizations

## Appendix A-1


### Analyst Certification

The research analyst(s) primarily responsible for the preparation and content of this research report are named in bold text in the author block at the front of the product except for those sections where an analyst's name appears in bold alongside content which is attributable to that analyst. Each of these analyst(s) certify, with respect to the section(s) of the report for which they are responsible, that the views expressed therein accurately reflect their personal views about each issuer and security referenced and were prepared in an independent manner, including with respect to Citigroup Global Markets Inc and its affiliates. No part of the research analyst's compensation was, is, or will be, directly or indirectly, related to the specific recommendation(s) or view(s) expressed by that research analyst in this report.

**IMPORTANT DISCLOSURES**

**Bajaj Auto (BAJA.BO)**  
**Ratings and Target Price History**  
**Fundamental Research**

Analyst: Jamshed Dadabhoy



Date	Rating	Target Price	Closing Price
1 8-Mar-11	3L	*1,390.00	1,386.75
2 21-Sep-11	3L	*1,522.00	1,603.20
3 5-Oct-11	3L	*1,430.00	1,497.80

Date	Rating	Target Price	Closing Price
4 7-Oct-11	Stock rating system changed		
5 7-Oct-11	*3	1,430.00	1,503.75
6 24-Oct-11	3	*1,540.00	1,691.70


Date	Rating	Target Price	Closing Price
7 22-Jan-12	3	*1,482.00	1,557.80
8 27-Mar-12	3	*1,570.00	1,660.20
9 19-Jul-12	*1	*1,835.00	1,549.20

\* Indicates change

Rating/target price changes above reflect Eastern Standard Time

**Bajaj Auto (BAJA.BO)**  
**Ratings and Target Price History**  
**Best Ideas Research**  
**Relative Call (3 Month)**

Analyst: Jamshed Dadabhoy



\* Indicates change

Rating/target price changes above reflect Eastern Standard Time

**Bajaj Auto Ltd (BAJA.BO)**  
**Rating History**  
**Global Quantitative Research**  
**Asia Radar Screen**

Analyst: Paul R Chanin



Date	Rating	Target Price	Closing Price
1 1-Jan-10	*2	-	880.85
2 29-Jan-10	*3	-	886.55
3 5-Feb-10	*2	-	841.80
4 19-Feb-10	*3	-	904.83
5 23-Apr-10	*4	-	1,053.63
6 14-May-10	*1	-	1,092.75
7 21-May-10	*2	-	1,049.65
8 26-Nov-10	*3	-	1,615.55
9 7-Jan-11	*2	-	1,317.00
10 14-Jan-11	*4	-	1,246.90
11 21-Jan-11	*3	-	1,311.55
12 18-Feb-11	*4	-	1,335.20
13 11-Mar-11	*2	-	1,374.20
14 18-Mar-11	*3	-	1,360.50

Date	Rating	Target Price	Closing Price
15 20-May-11	*2	-	1,330.45
16 27-May-11	*3	-	1,314.30
17 3-Jun-11	*4	-	1,371.90
18 10-Jun-11	*1	-	1,325.50
19 24-Jun-11	*4	-	1,382.70
20 15-Jul-11	*1	-	1,418.80
21 5-Aug-11	*3	-	1,400.30
22 12-Aug-11	*4	-	1,457.30
23 19-Aug-11	*2	-	1,431.20
24 26-Aug-11	*3	-	1,503.90
25 16-Sep-11	*2	-	1,625.55
26 30-Sep-11	*1	-	1,534.35
27 25-Nov-11	*2	-	1,642.70
28 6-Jan-12	*1	-	1,459.20

Date	Rating	Target Price	Closing Price
29 13-Apr-12	*2	-	1,640.70
30 27-Apr-12	*1	-	1,582.55
31 11-May-12	*2	-	1,555.20
32 25-May-12	*3	-	1,496.35
33 8-Jun-12	*4	-	1,528.65
34 22-Jun-12	*3	-	1,545.30
35 29-Jun-12	*4	-	1,572.00
36 13-Jul-12	*5	-	1,497.15
37 20-Jul-12	*3	-	1,590.60
38 17-Aug-12	*4	-	1,696.50
39 5-Oct-12	*5	-	1,751.05
40 16-Nov-12	*4	-	1,813.60
41 23-Nov-12	*3	-	1,816.70


\* Indicates change

Rating/target price changes above reflect Eastern Standard Time

**Bajaj Auto Ltd (BAJA.BO)**

Rating History  
Global Quantitative Research  
World Radar Screen

Analyst: Chris Montagu



	Date	Rating	Target Price	Closing Price
1	1-Apr-10	*4	-	999.73
2	1-May-10	*8	-	1,047.15
3	1-Jun-10	*3	-	1,085.03
4	1-Jul-10	*4	-	1,248.23
5	1-Aug-10	*3	-	1,344.03
6	1-Dec-10	*7	-	1,569.85
7	1-Jan-11	*3	-	1,541.50
8	1-Feb-11	*5	-	1,246.25

	Date	Rating	Target Price	Closing Price
9	1-Mar-11	*8	-	1,334.85
10	1-Apr-11	*7	-	1,459.50
11	1-May-11	*5	-	1,462.80
12	1-Jun-11	*8	-	1,338.55
13	7-Jul-11	*10	-	1,454.95
14	9-Aug-11	*7	-	1,427.35
15	9-Sep-11	*9	-	1,625.70
16	6-Oct-11	*4	-	1,497.80

	Date	Rating	Target Price	Closing Price
17	10-Jan-12	*3	-	1,429.55
18	9-Mar-12	*5	-	1,749.50
19	10-Apr-12	*4	-	1,647.20
20	4-May-12	*3	-	1,501.75
21	7-Jun-12	*7	-	1,545.10
22	3-Jul-12	*8	-	1,562.05
23	6-Nov-12	*9	-	1,849.05
24	8-Jan-13	*4	-	2,198.80

\* Indicates change

Rating/target price changes above reflect Eastern Standard Time

Citigroup Global Markets Inc. or its affiliates beneficially owns 1% or more of any class of common equity securities of Tata Motors. This position reflects information available as of the prior business day.

Within the past 12 months, Citigroup Global Markets Inc. or its affiliates has acted as manager or co-manager of an offering of securities of Tata Motors, Mahindra & Mahindra, Honda Motor.

Citigroup Global Markets Inc. or its affiliates has received compensation for investment banking services provided within the past 12 months from Tata Motors, Mahindra & Mahindra, Honda Motor.

Citigroup Global Markets Inc. or an affiliate received compensation for products and services other than investment banking services from Tata Motors, Mahindra & Mahindra, Maruti Suzuki India, Hero MotoCorp, Yamaha Motor, Honda Motor, Bajaj Auto in the past 12 months.

Citigroup Global Markets Inc. currently has, or had within the past 12 months, the following as investment banking client(s): Tata Motors, Mahindra & Mahindra, Honda Motor.

Citigroup Global Markets Inc. currently has, or had within the past 12 months, the following as clients, and the services provided were non-investment-banking, securities-related: Tata Motors, Mahindra & Mahindra, Maruti Suzuki India, Hero MotoCorp, Yamaha Motor, Honda Motor, Bajaj Auto.

Citigroup Global Markets Inc. currently has, or had within the past 12 months, the following as clients, and the services provided were non-investment-banking, non-securities-related: Tata Motors, Mahindra & Mahindra, Maruti Suzuki India, Hero MotoCorp, Yamaha Motor, Honda Motor, Bajaj Auto.

Analysts' compensation is determined based upon activities and services intended to benefit the investor clients of Citigroup Global Markets Inc. and its affiliates ("the Firm"). Like all Firm employees, analysts receive compensation that is impacted by overall firm profitability which includes investment banking revenues.

For important disclosures (including copies of historical disclosures) regarding the companies that are the subject of this Citi Research product ("the Product"), please contact Citi Research, 388 Greenwich Street, 28th Floor, New York, NY, 10013, Attention: Legal/Compliance [E6WYB6412478]. In addition, the same important disclosures, with the exception of the Valuation and Risk assessments and historical disclosures, are contained on the Firm's disclosure website at [https://www.citivelocity.com/cvr/eppublic/citi\\_research\\_disclosures](https://www.citivelocity.com/cvr/eppublic/citi_research_disclosures). Valuation and Risk assessments can be found in the text of the most recent research note/report regarding the subject company. Historical disclosures (for up to the past three years) will be provided upon request.

**Citi Research Equity Ratings Distribution**

Data current as of 31 Dec 2012

	12 Month Rating			Relative Rating		
	Buy	Hold	Sell	Buy	Hold	Sell
Citi Research Global Fundamental Coverage	49%	38%	12%	7%	86%	7%
<i>% of companies in each rating category that are investment banking clients</i>	53%	49%	45%	60%	49%	55%
Citi Research Quantitative World Radar Screen Model Coverage	30%	40%	30%			
<i>% of companies in each rating category that are investment banking clients</i>	31%	28%	24%			
Citi Research Quantitative Decision Tree Model Coverage	46%	0%	54%			
<i>% of companies in each rating category that are investment banking clients</i>	64%	0%	50%			
Citi Research Asia Quantitative Radar Screen Model Coverage	20%	60%	20%			
<i>% of companies in each rating category that are investment banking clients</i>	33%	26%	26%			
Citi Research Australia Radar Model Coverage	42%	0%	58%			
<i>% of companies in each rating category that are investment banking clients</i>	33%	0%	19%			



#### Guide to Citi Research Fundamental Research Investment Ratings:

Citi Research stock recommendations include an investment rating and an optional risk rating to highlight high risk stocks.

**Risk rating** takes into account both price volatility and fundamental criteria. Stocks will either have no risk rating or a High risk rating assigned.

**Investment Ratings:** Citi Research investment ratings are Buy, Neutral and Sell. Our ratings are a function of analyst expectations of expected total return ("ETR") and risk. ETR is the sum of the forecast price appreciation (or depreciation) plus the dividend yield for a stock within the next 12 months. The Investment rating definitions are: Buy (1) ETR of 15% or more or 25% or more for High risk stocks; and Sell (3) for negative ETR. Any covered stock not assigned a Buy or a Sell is a Neutral (2). For stocks rated Neutral (2), if an analyst believes that there are insufficient valuation drivers and/or investment catalysts to derive a positive or negative investment view, they may elect with the approval of Citi Research management not to assign a target price and, thus, not derive an ETR. Analysts may place covered stocks "Under Review" in response to exceptional circumstances (e.g. lack of information critical to the analyst's thesis) affecting the company and / or trading in the company's securities (e.g. trading suspension). As soon as practically possible, the analyst will publish a note re-establishing a rating and investment thesis. To satisfy regulatory requirements, we correspond Under Review and Neutral to Hold in our ratings distribution table for our 12-month fundamental rating system. However, we reiterate that we do not consider Under Review to be a recommendation.

**Relative three-month ratings:** Citi Research may also assign a three-month relative call (or rating) to a stock to highlight expected out-performance (most preferred) or under-performance (least preferred) versus the geographic and industry sector over a 3 month period. The relative call may highlight a specific near-term catalyst or event impacting the company or the market that is anticipated to have a short-term price impact on the equity securities of the company. Absent any specific catalyst the analyst(s) will indicate the most and least preferred stocks in the universe of stocks under consideration, explaining the basis for this short-term view. This three-month view may be different from and does not affect a stock's fundamental equity rating, which reflects a longer-term total absolute return expectation. For purposes of NASD/NYSE ratings-distribution-disclosure rules, most preferred calls correspond to a buy recommendation and least preferred calls correspond to a sell recommendation. Any stock not assigned to a most preferred or least preferred call is considered non-relative-rated (NRR). For purposes of NASD/NYSE ratings-distribution-disclosure rules we correspond NRR to Hold in our ratings distribution table for our 3-month relative rating system. However, we reiterate that we do not consider NRR to be a recommendation.

---

Prior to October 8, 2011, the firm's stock recommendation system included a risk rating and an investment rating. **Risk ratings**, which took into account both price volatility and fundamental criteria, were: Low (L), Medium (M), High (H), and Speculative (S). **Investment Ratings** of Buy, Hold and Sell were a function of the Citi Research expectation of total return (forecast price appreciation and dividend yield within the next 12 months) and risk rating. Additionally, analysts could have placed covered stocks "Under Review" in response to exceptional circumstances (e.g. lack of information critical to the analyst's thesis) affecting the company and/or trading in the company's securities (e.g. trading suspension). Stocks placed "Under Review" were monitored daily by management and as practically possible, the analyst published a note re-establishing a rating and investment thesis. For securities in developed markets (US, UK, Europe, Japan, and Australia/New Zealand), investment ratings were: Buy (1) (expected total return of 10% or more for Low-Risk stocks, 15% or more for Medium-Risk stocks, 20% or more for High-Risk stocks, and 35% or more for Speculative stocks); Hold (2) (0%-10% for Low-Risk stocks, 0%-15% for Medium-Risk stocks, 0%-20% for High-Risk stocks, and 0%-35% for Speculative stocks); and Sell (3) (negative total return). For securities in emerging markets (Asia Pacific, Emerging Europe/Middle East/Africa, and Latin America), investment ratings were: Buy (1) (expected total return of 15% or more for Low-Risk stocks, 20% or more for Medium-Risk stocks, 30% or more for High-Risk stocks, and 40% or more for Speculative stocks); Hold (2) (5%-15% for Low-Risk stocks, 10%-20% for Medium-Risk stocks, 15%-30% for High-Risk stocks, and 20%-40% for Speculative stocks); and Sell (3) (5% or less for Low-Risk stocks, 10% or less for Medium-Risk stocks, 15% or less for High-Risk stocks, and 20% or less for Speculative stocks).

---

Investment ratings are determined by the ranges described above at the time of initiation of coverage, a change in investment and/or risk rating, or a change in target price (subject to limited management discretion). At other times, the expected total returns may fall outside of these ranges because of market price movements and/or other short-term volatility or trading patterns. Such interim deviations from specified ranges will be permitted but will become subject to review by Research Management. Your decision to buy or sell a security should be based upon your personal investment objectives and should be made only after evaluating the stock's expected performance and risk.

#### Guide to Citi Research Quantitative Research Investment Ratings:

Citi Research Quantitative Research World Radar Screen recommendations are based on a globally consistent framework to measure relative value and momentum for a large number of stocks across global developed and emerging markets. Relative value and momentum rankings are equally weighted to produce a global attractiveness score for each stock. The scores are then ranked and put into deciles. A stock with a decile rating of 1 denotes an attractiveness score in the top 10% of the universe (most attractive). A stock with a decile rating of 10 denotes an attractiveness score in the bottom 10% of the universe (least attractive).

Citi Research Asia Quantitative Radar Screen model recommendations are based on a regionally consistent framework to measure relative value and momentum for a large number of stocks across regional developed and emerging markets. Relative value and momentum rankings are equally weighted to produce a global attractiveness score for each stock. The scores are then ranked and put into quintiles. A stock with a quintile rating of 1 denotes an attractiveness score in the top 20% of the universe (most attractive). A stock with a quintile rating of 5 denotes an attractiveness score in the bottom 20% of the universe (least attractive).

Citi Research Australia Quantitative Radar Screen model recommendations are based on a robust framework to measure relative value and momentum for a large number of stocks across the Australian market. Stocks with a ranking of 1 denotes a stock that is above average in terms of both value and momentum relative to the stocks in the Australian market. A ranking of 10 denotes a stock that is below average in terms of both value and momentum relative to the stocks in the Australian market.

Citi Research Quantitative Decision Tree model recommendations are based on a predetermined set of factors to rate the relative attractiveness of stocks. These factors are detailed in the text of the report. The Decision Tree model forecasts whether stocks are attractive or unattractive relative to other stocks in the same sector (based on the Russell 1000 sector classifications).

---

For purposes of NASD/NYSE ratings-distribution-disclosure rules, a Citi Research Quantitative World Radar Screen recommendation of (1), (2) or (3) most closely corresponds to a buy recommendation; a recommendation from this product group of (4), (5), (6) or (7) most closely corresponds to a hold recommendation; and a recommendation of (8), (9) or (10) most closely corresponds to a sell recommendation. An (NR) recommendation indicates that the stock is no longer in the screen.

For purposes of NASD/NYSE ratings distribution disclosure rules, a Citi Research Asia Quantitative Radar Screen recommendation of (1) most closely

corresponds to a buy recommendation; a Citi Research Asia Quantitative Radar Screen recommendation of (2), (3), (4) most closely corresponds to a hold recommendation; and a recommendation of (5) most closely corresponds to a sell recommendation. An (NR) recommendation indicates that the stock is no longer in the screen.

For purposes of NASD/NYSE ratings-distribution-disclosure rules, a Citi Research Quantitative Research Decision Tree model or Quantitative Research Australia Radar Screen recommendation of "attractive" (1) most closely corresponds to a buy recommendation. All other stocks in the sector are considered to be "unattractive" (10) which most closely corresponds to a sell recommendation. An (NR)/(0) recommendation indicates that the stock is no longer in the screen.

Recommendations are based on the relative attractiveness of a stock, thus can not be directly equated to buy, hold and sell categories. Accordingly, your decision to buy or sell a security should be based on your personal investment objectives and only after evaluating the stock's expected relative performance.

---

#### NON-US RESEARCH ANALYST DISCLOSURES

Non-US research analysts who have prepared this report (i.e., all research analysts listed below other than those identified as employed by Citigroup Global Markets Inc.) are not registered/qualified as research analysts with FINRA. Such research analysts may not be associated persons of the member organization and therefore may not be subject to the NYSE Rule 472 and NASD Rule 2711 restrictions on communications with a subject company, public appearances and trading securities held by a research analyst account. The legal entities employing the authors of this report are listed below:

Citigroup Global Markets Singapore PTE LIMITED	Jamshed Dadabhoj; Paul R Chanin
Citigroup Global Markets India Private Limited	Arvind Sharma
Citigroup Global Markets Japan Inc.	Noriyuki Matsushima
Citigroup Global Markets Ltd	Chris Montagu

---

#### OTHER DISCLOSURES

The subject company's share price set out on the front page of this Product is quoted as at 01 February 2013 04:00 PM on the issuer's primary market.

Citigroup Global Markets Inc. and/or its affiliates has a significant financial interest in relation to Tata Motors, Yamaha Motor. (For an explanation of the determination of significant financial interest, please refer to the policy for managing conflicts of interest which can be found at [www.citiVelocity.com](http://www.citiVelocity.com).)

This Product has been modified by the author following a discussion with one or more of the named issuers/issuers of the named securities.

For securities recommended in the Product in which the Firm is not a market maker, the Firm is a liquidity provider in the issuers' financial instruments and may act as principal in connection with such transactions. The Firm is a regular issuer of traded financial instruments linked to securities that may have been recommended in the Product. The Firm regularly trades in the securities of the issuer(s) discussed in the Product. The Firm may engage in securities transactions in a manner inconsistent with the Product and, with respect to securities covered by the Product, will buy or sell from customers on a principal basis.

Securities recommended, offered, or sold by the Firm: (i) are not insured by the Federal Deposit Insurance Corporation; (ii) are not deposits or other obligations of any insured depository institution (including Citibank); and (iii) are subject to investment risks, including the possible loss of the principal amount invested. Although information has been obtained from and is based upon sources that the Firm believes to be reliable, we do not guarantee its accuracy and it may be incomplete and condensed. Note, however, that the Firm has taken all reasonable steps to determine the accuracy and completeness of the disclosures made in the Important Disclosures section of the Product. The Firm's research department has received assistance from the subject company(ies) referred to in this Product including, but not limited to, discussions with management of the subject company(ies). Firm policy prohibits research analysts from sending draft research to subject companies. However, it should be presumed that the author of the Product has had discussions with the subject company to ensure factual accuracy prior to publication. All opinions, projections and estimates constitute the judgment of the author as of the date of the Product and these, plus any other information contained in the Product, are subject to change without notice. Prices and availability of financial instruments also are subject to change without notice. Notwithstanding other departments within the Firm advising the companies discussed in this Product, information obtained in such role is not used in the preparation of the Product. Although Citi Research does not set a predetermined frequency for publication, if the Product is a fundamental research report, it is the intention of Citi Research to provide research coverage of the/those issuer(s) mentioned therein, including in response to news affecting this issuer, subject to applicable quiet periods and capacity constraints. The Product is for informational purposes only and is not intended as an offer or solicitation for the purchase or sale of a security. Any decision to purchase securities mentioned in the Product must take into account existing public information on such security or any registered prospectus.

Investing in non-U.S. securities, including ADRs, may entail certain risks. The securities of non-U.S. issuers may not be registered with, nor be subject to the reporting requirements of the U.S. Securities and Exchange Commission. There may be limited information available on foreign securities. Foreign companies are generally not subject to uniform audit and reporting standards, practices and requirements comparable to those in the U.S. Securities of some foreign companies may be less liquid and their prices more volatile than securities of comparable U.S. companies. In addition, exchange rate movements may have an adverse effect on the value of an investment in a foreign stock and its corresponding dividend payment for U.S. investors. Net dividends to ADR investors are estimated, using withholding tax rates conventions, deemed accurate, but investors are urged to consult their tax advisor for exact dividend computations. Investors who have received the Product from the Firm may be prohibited in certain states or other jurisdictions from purchasing securities mentioned in the Product from the Firm. Please ask your Financial Consultant for additional details. Citigroup Global Markets Inc. takes responsibility for the Product in the United States. Any orders by US investors resulting from the information contained in the Product may be placed only through Citigroup Global Markets Inc.

**Important Disclosures for Morgan Stanley Smith Barney LLC Customers:** Morgan Stanley & Co. LLC (Morgan Stanley) research reports may be available about the companies that are the subject of this Citi Research research report. Ask your Financial Advisor or use [smithbarney.com](http://smithbarney.com) to view any available Morgan Stanley research reports in addition to Citi Research research reports.

Important disclosure regarding the relationship between the companies that are the subject of this Citi Research research report and Morgan Stanley Smith Barney LLC and its affiliates are available at the Morgan Stanley Smith Barney disclosure website at

www.morganstanleysmithbarney.com/researchdisclosures.

For Morgan Stanley and Citigroup Global Markets, Inc. specific disclosures, you may refer to www.morganstanley.com/researchdisclosures and [https://www.citivelocity.com/cvr/eppublic/citi\\_research\\_disclosures](https://www.citivelocity.com/cvr/eppublic/citi_research_disclosures).

This Citi Research research report has been reviewed and approved on behalf of Morgan Stanley Smith Barney LLC. This review and approval was conducted by the same person who reviewed this research report on behalf of Citi Research. This could create a conflict of interest.

**The Citigroup legal entity that takes responsibility for the production of the Product is the legal entity which the first named author is employed by.** The Product is made available in **Australia** through Citi Global Markets Australia Pty Ltd. (ABN 64 003 114 832 and AFSL No. 240992), participant of the ASX Group and regulated by the Australian Securities & Investments Commission. Citigroup Centre, 2 Park Street, Sydney, NSW 2000. The Product is made available in Australia to Private Banking wholesale clients through Citigroup Pty Limited (ABN 88 004 325 080 and AFSL 238098). Citigroup Pty Limited provides all financial product advice to Australian Private Banking wholesale clients through bankers and relationship managers. If there is any doubt about the suitability of investments held in Citigroup Private Bank accounts, investors should contact the Citigroup Private Bank in Australia. Citigroup companies may compensate affiliates and their representatives for providing products and services to clients. The Product is made available in **Brazil** by Citigroup Global Markets Brasil - CCTVM SA, which is regulated by CVM - Comissão de Valores Mobiliários, BACEN - Brazilian Central Bank, APIMEC - Associação dos Analistas e Profissionais de Investimento do Mercado de Capitais and ANBID - Associação Nacional dos Bancos de Investimento. Av. Paulista, 1111 - 11º andar - CEP. 01311920 - São Paulo - SP. If the Product is being made available in certain provinces of **Canada** by Citigroup Global Markets (Canada) Inc. ("CGM Canada"), CGM Canada has approved the Product. Citigroup Place, 123 Front Street West, Suite 1100, Toronto, Ontario M5J 2M3. This product is available in **Chile** through Banchile Corredores de Bolsa S.A., an indirect subsidiary of Citigroup Inc., which is regulated by the Superintendencia de Valores y Seguros. Agustinas 975, piso 2, Santiago, Chile. The Product is made available in **France** by Citigroup Global Markets Limited, which is authorised and regulated by Financial Services Authority. 1-5 Rue Paul Cézanne, 8ème, Paris, France. The Product is distributed in **Germany** by Citigroup Global Markets Deutschland AG ("CGMD"), which is regulated by Bundesanstalt fuer Finanzdienstleistungsaufsicht (BaFin). CGMD, Reuterweg 16, 60323 Frankfurt am Main. Research which relates to "securities" (as defined in the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong)) is issued in **Hong Kong** by, or on behalf of, Citigroup Global Markets Asia Limited which takes full responsibility for its content. Citigroup Global Markets Asia Ltd. is regulated by Hong Kong Securities and Futures Commission. If the Research is made available through Citibank, N.A., Hong Kong Branch, for its clients in Citi Private Bank, it is made available by Citibank N.A., Citibank Tower, Citibank Plaza, 3 Garden Road, Hong Kong. Citibank N.A. is regulated by the Hong Kong Monetary Authority. Please contact your Private Banker in Citibank N.A., Hong Kong, Branch if you have any queries on or any matters arising from or in connection with this document. The Product is made available in **India** by Citigroup Global Markets India Private Limited, which is regulated by Securities and Exchange Board of India. Bakhtawar, Nariman Point, Mumbai 400-021. The Product is made available in **Indonesia** through PT Citigroup Securities Indonesia. 5/F, Citibank Tower, Bapindo Plaza, Jl. Jend. Sudirman Kav. 54-55, Jakarta 12190. Neither this Product nor any copy hereof may be distributed in Indonesia or to any Indonesian citizens wherever they are domiciled or to Indonesian residents except in compliance with applicable capital market laws and regulations. This Product is not an offer of securities in Indonesia. The securities referred to in this Product have not been registered with the Capital Market and Financial Institutions Supervisory Agency (BAPEPAM-LK) pursuant to relevant capital market laws and regulations, and may not be offered or sold within the territory of the Republic of Indonesia or to Indonesian citizens through a public offering or in circumstances which constitute an offer within the meaning of the Indonesian capital market laws and regulations. The Product is made available in **Israel** through Citibank NA, regulated by the Bank of Israel and the Israeli Securities Authority. Citibank, N.A., Platinum Building, 21 Ha'arba'ah St, Tel Aviv, Israel. The Product is made available in **Italy** by Citigroup Global Markets Limited, which is authorised and regulated by Financial Services Authority. Via dei Mercanti, 12, Milan, 20121, Italy. The Product is made available in **Japan** by Citigroup Global Markets Japan Inc. ("CGMJ"), which is regulated by Financial Services Agency, Securities and Exchange Surveillance Commission, Japan Securities Dealers Association, Tokyo Stock Exchange and Osaka Securities Exchange. Shin-Marunouchi Building, 1-5-1 Marunouchi, Chiyoda-ku, Tokyo 100-6520 Japan. If the Product was distributed by SMBC Nikko Securities Inc. it is being so distributed under license. In the event that an error is found in an CGMJ research report, a revised version will be posted on the Firm's Citi Velocity website. If you have questions regarding Citi Velocity, please call (81 3) 6270-3019 for help. The Product is made available in **Korea** by Citigroup Global Markets Korea Securities Ltd., which is regulated by the Financial Services Commission, the Financial Supervisory Service and the Korea Financial Investment Association (KOFIA). Citibank Building, 39 Da-dong, Jung-gu, Seoul 100-180, Korea. KOFIA makes available registration information of research analysts on its website. Please visit the following website if you wish to find KOFIA registration information on research analysts of Citigroup Global Markets Korea Securities Ltd. <http://dis.kofia.or.kr/fs/dis2/fundMgr/DISFundMgrAnalystPop.jsp?companyCd2=A03030&pageDiv=02>. The Product is made available in Korea by Citibank Korea Inc., which is regulated by the Financial Services Commission and the Financial Supervisory Service. Address is Citibank Building, 39 Da-dong, Jung-gu, Seoul 100-180, Korea. The Product is made available in **Malaysia** by Citigroup Global Markets Malaysia Sdn Bhd (Company No. 460819-D) ("CGMM") to its clients and CGMM takes responsibility for its contents. CGMM is regulated by the Securities Commission of Malaysia. Please contact CGMM at Level 43 Menara Citibank, 165 Jalan Ampang, 50450 Kuala Lumpur, Malaysia in respect of any matters arising from, or in connection with, the Product. The Product is made available in **Mexico** by Acciones y Valores Banamex, S.A. De C. V., Casa de Bolsa, Integrante del Grupo Financiero Banamex ("Accival") which is a wholly owned subsidiary of Citigroup Inc. and is regulated by Comisión Nacional Bancaria y de Valores. Reforma 398, Col. Juárez, 06600 Mexico, D.F. In **New Zealand** the Product is made available to 'wholesale clients' only as defined by s5C(1) of the Financial Advisers Act 2008 ('FAA') through Citigroup Global Markets Australia Pty Ltd (ABN 64 003 114 832 and AFSL No. 240992), an overseas financial adviser as defined by the FAA, participant of the ASX Group and regulated by the Australian Securities & Investments Commission. Citigroup Centre, 2 Park Street, Sydney, NSW 2000. The Product is made available in **Pakistan** by Citibank N.A. Pakistan branch, which is regulated by the State Bank of Pakistan and Securities Exchange Commission, Pakistan. AWT Plaza, 1.1. Chundrigar Road, P.O. Box 4889, Karachi-74200. The Product is made available in the **Philippines** through Citicorp Financial Services and Insurance Brokerage Philippines, Inc., which is regulated by the Philippines Securities and Exchange Commission. 20th Floor Citibank Square Bldg. The Product is made available in the Philippines through Citibank NA Philippines branch, Citibank Tower, 8741 Paseo De Roxas, Makati City, Manila. Citibank NA Philippines NA is regulated by The Bangko Sentral ng Pilipinas. The Product is made available in **Poland** by Dom Maklerski Banku Handlowego SA an indirect subsidiary of Citigroup Inc., which is regulated by Komisja Nadzoru Finansowego. Dom Maklerski Banku Handlowego S.A. ul.Senatorska 16, 00-923 Warszawa. The Product is made available in the **Russian Federation** through ZAO Citibank, which is licensed to carry out banking activities in the Russian Federation in accordance with the general banking license issued by the Central Bank of the Russian Federation and brokerage activities in accordance with the license issued by the Federal Service for Financial Markets. Neither the Product nor any information contained in the Product shall be considered as advertising the securities mentioned in this report within the territory of the Russian Federation or outside the Russian Federation. The Product does not constitute an appraisal within the meaning of the Federal Law of the Russian Federation of 29 July

1998 No. 135-FZ (as amended) On Appraisal Activities in the Russian Federation. 8-10 Gasheka Street, 125047 Moscow. The Product is made available in **Singapore** through Citigroup Global Markets Singapore Pte. Ltd. ("CGMSPL"), a capital markets services license holder, and regulated by Monetary Authority of Singapore. Please contact CGMSPL at 8 Marina View, 21st Floor Asia Square Tower 1, Singapore 018960, in respect of any matters arising from, or in connection with, the analysis of this document. This report is intended for recipients who are accredited, expert and institutional investors as defined under the Securities and Futures Act (Cap. 289). The Product is made available by The Citigroup Private Bank in Singapore through Citibank, N.A., Singapore Branch, a licensed bank in Singapore that is regulated by Monetary Authority of Singapore. Please contact your Private Banker in Citibank N.A., Singapore Branch if you have any queries on or any matters arising from or in connection with this document. This report is intended for recipients who are accredited, expert and institutional investors as defined under the Securities and Futures Act (Cap. 289). This report is distributed in Singapore by Citibank Singapore Ltd ("CSL") to selected Citigold/Citigold Private Clients. CSL provides no independent research or analysis of the substance or in preparation of this report. Please contact your Citigold/Citigold Private Client Relationship Manager in CSL if you have any queries on or any matters arising from or in connection with this report. This report is intended for recipients who are accredited investors as defined under the Securities and Futures Act (Cap. 289). Citigroup Global Markets (Pty) Ltd. is incorporated in the **Republic of South Africa** (company registration number 2000/025866/07) and its registered office is at 145 West Street, Sandton, 2196, Saxonwold. Citigroup Global Markets (Pty) Ltd. is regulated by JSE Securities Exchange South Africa, South African Reserve Bank and the Financial Services Board. The investments and services contained herein are not available to private customers in South Africa. The Product is made available in **Spain** by Citigroup Global Markets Limited, which is authorised and regulated by Financial Services Authority. 29 Jose Ortega Y Gasset, 4th Floor, Madrid, 28006, Spain. The Product is made available in the **Republic of China** through Citigroup Global Markets Taiwan Securities Company Ltd. ("CGMTS"), 14 and 15F, No. 1, Songzhi Road, Taipei 110, Taiwan and/or through Citibank Securities (Taiwan) Company Limited ("CSTL"), 14 and 15F, No. 1, Songzhi Road, Taipei 110, Taiwan, subject to the respective license scope of each entity and the applicable laws and regulations in the Republic of China. CGMTS and CSTL are both regulated by the Securities and Futures Bureau of the Financial Supervisory Commission of Taiwan, the Republic of China. No portion of the Product may be reproduced or quoted in the Republic of China by the press or any third parties [without the written authorization of CGMTS and CSTL]. If the Product covers securities which are not allowed to be offered or traded in the Republic of China, neither the Product nor any information contained in the Product shall be considered as advertising the securities or making recommendation of the securities in the Republic of China. The Product is for informational purposes only and is not intended as an offer or solicitation for the purchase or sale of a security or financial products. Any decision to purchase securities or financial products mentioned in the Product must take into account existing public information on such security or the financial products or any registered prospectus. The Product is made available in **Thailand** through Citicorp Securities (Thailand) Ltd., which is regulated by the Securities and Exchange Commission of Thailand. 18/F, 22/F and 29/F, 82 North Sathorn Road, Silom, Bangrak, Bangkok 10500, Thailand. The Product is made available in **Turkey** through Citibank AS which is regulated by Capital Markets Board. Tekfen Tower, Eski Buyukdere Caddesi # 209 Kat 2B, 23294 Levent, Istanbul, Turkey. In the **U.A.E**, these materials (the "Materials") are communicated by Citigroup Global Markets Limited, DIFC branch ("CGML"), an entity registered in the Dubai International Financial Center ("DIFC") and licensed and regulated by the Dubai Financial Services Authority ("DFSA") to Professional Clients and Market Counterparties only and should not be relied upon or distributed to Retail Clients. A distribution of the different Citi Research ratings distribution, in percentage terms for Investments in each sector covered is made available on request. Financial products and/or services to which the Materials relate will only be made available to Professional Clients and Market Counterparties. The Product is made available in **United Kingdom** by Citigroup Global Markets Limited, which is authorised and regulated by Financial Services Authority. This material may relate to investments or services of a person outside of the UK or to other matters which are not regulated by the FSA and further details as to where this may be the case are available upon request in respect of this material. Citigroup Centre, Canada Square, Canary Wharf, London, E14 5LB. The Product is made available in **United States** by Citigroup Global Markets Inc, which is a member of FINRA and registered with the US Securities and Exchange Commission. 388 Greenwich Street, New York, NY 10013. Unless specified to the contrary, within EU Member States, the Product is made available by Citigroup Global Markets Limited, which is regulated by Financial Services Authority. Pursuant to Comissão de Valores Mobiliários Rule 483, Citi is required to disclose whether a Citi related company or business has a commercial relationship with the subject company. Considering that Citi operates multiple businesses in more than 100 countries around the world, it is likely that Citi has a commercial relationship with the subject company.

Many European regulators require that a firm must establish, implement and make available a policy for managing conflicts of interest arising as a result of publication or distribution of investment research. The policy applicable to Citi Research's Products can be found at [https://www.citivelocity.com/cvr/eppublic/citi\\_research\\_disclosures](https://www.citivelocity.com/cvr/eppublic/citi_research_disclosures).

Compensation of equity research analysts is determined by equity research management and Citigroup's senior management and is not linked to specific transactions or recommendations.

The Product may have been distributed simultaneously, in multiple formats, to the Firm's worldwide institutional and retail customers. The Product is not to be construed as providing investment services in any jurisdiction where the provision of such services would not be permitted.

Subject to the nature and contents of the Product, the investments described therein are subject to fluctuations in price and/or value and investors may get back less than originally invested. Certain high-volatility investments can be subject to sudden and large falls in value that could equal or exceed the amount invested. Certain investments contained in the Product may have tax implications for private customers whereby levels and basis of taxation may be subject to change. If in doubt, investors should seek advice from a tax adviser. The Product does not purport to identify the nature of the specific market or other risks associated with a particular transaction. Advice in the Product is general and should not be construed as personal advice given it has been prepared without taking account of the objectives, financial situation or needs of any particular investor. Accordingly, investors should, before acting on the advice, consider the appropriateness of the advice, having regard to their objectives, financial situation and needs. Prior to acquiring any financial product, it is the client's responsibility to obtain the relevant offer document for the product and consider it before making a decision as to whether to purchase the product. With the exception of our product that is made available only to Qualified Institutional Buyers (QIBs) and other product that is made available through other distribution channels only to certain categories of clients to satisfy legal or regulatory requirements, Citi Research concurrently disseminates its research via proprietary and non-proprietary electronic distribution platforms. Periodically, individual Citi Research analysts may also opt to circulate research posted on such platforms to one or more clients by email. Such email distribution is discretionary and is done only after the research has been disseminated via the aforementioned distribution channels. Citi Research simultaneously distributes product that is limited to QIBs only through email distribution.

The level and types of services provided by Citi Research analysts to clients may vary depending on various factors such as the client's individual preferences as to the frequency and manner of receiving communications from analysts, the client's risk profile and investment focus and perspective (e.g. market-wide, sector specific, long term, short-term etc.), the size and scope of the overall client relationship with Citi and legal and regulatory constraints.

Citi Research product may source data from dataCentral. dataCentral is a Citi Research proprietary database, which includes Citi estimates, data from company reports and feeds from Reuters and Datastream.

---

© 2013 Citigroup Global Markets Inc. Citi Research is a division of Citigroup Global Markets Inc. Citi and Citi with Arc Design are trademarks and service marks of Citigroup Inc. and its affiliates and are used and registered throughout the world. All rights reserved. Any unauthorized use, duplication, redistribution or disclosure of this report (the "Product"), including, but not limited to, redistribution of the Product by electronic mail, posting of the Product on a website or page, and/or providing to a third party a link to the Product, is prohibited by law and will result in prosecution. The information contained in the Product is intended solely for the recipient and may not be further distributed by the recipient to any third party. Where included in this report, MSCI sourced information is the exclusive property of Morgan Stanley Capital International Inc. (MSCI). Without prior written permission of MSCI, this information and any other MSCI intellectual property may not be reproduced, disseminated or used to create any financial products, including any indices. This information is provided on an "as is" basis. The user assumes the entire risk of any use made of this information. MSCI, its affiliates and any third party involved in, or related to, computing or compiling the information hereby expressly disclaim all warranties of originality, accuracy, completeness, merchantability or fitness for a particular purpose with respect to any of this information. Without limiting any of the foregoing, in no event shall MSCI, any of its affiliates or any third party involved in, or related to, computing or compiling the information have any liability for any damages of any kind. MSCI, Morgan Stanley Capital International and the MSCI indexes are services marks of MSCI and its affiliates. The Firm accepts no liability whatsoever for the actions of third parties. The Product may provide the addresses of, or contain hyperlinks to, websites. Except to the extent to which the Product refers to website material of the Firm, the Firm has not reviewed the linked site. Equally, except to the extent to which the Product refers to website material of the Firm, the Firm takes no responsibility for, and makes no representations or warranties whatsoever as to, the data and information contained therein. Such address or hyperlink (including addresses or hyperlinks to website material of the Firm) is provided solely for your convenience and information and the content of the linked site does not in anyway form part of this document. Accessing such website or following such link through the Product or the website of the Firm shall be at your own risk and the Firm shall have no liability arising out of, or in connection with, any such referenced website.

---

ADDITIONAL INFORMATION IS AVAILABLE UPON REQUEST

---